ASCP Annual Meeting: Training Residents in Genomics Workshop

I wanted to devote this blog to my experience at the recent Training Residents in Genomics (TRIG) one-day workshop at the ASCP Annual Meeting in Chicago. I admit that I am biased since I had ten years molecular and cell biology and transgenics research experience prior to medical school and enjoy all things molecular. But I really I do think that TRIG is an idea whose time has come.

TRIG is a group of molecular pathologists, medical educators, and geneticists who came together in 2010 with the goal to create a standardized, high quality genomics curriculum and to promote adoption at >90% of pathology residency programs by the end of their 5-year grant period. A 2010 survey of 42 pathology residency program directors found that only 93% confirmed molecular pathology as a part of their training and only 31% had established curricula on relevant topics. So, TRIG plans to provide online resources, lectures and workshops, and to assess the efficacy of genomic medicine curricula at residency programs through RISE performance. From speaking to other residents I’ve met over the past year, I know that the teaching of molecular pathology at each program can vary significantly.

The TRIG workshop had four sessions that followed the case of a woman with newly diagnosed breast cancer while applying specific hands-on skills related to the genomic related elements of her case. I missed the first session so I can’t say too much except that they discussed single gene testing and assessment of BRCA mutations of unknown clinical significance. Session two covered the assessment of prognostic gene panels (Oncotype DX) and compared them versus the standard breast IHC panel. We also learned to plot Kaplan-Meier survival curves based on a patient’s genomic profile on a publicly available website.

After lunch, session three dealt with the selection of genes to design a breast cancer multi-gene assay for this patient. Questions considered were the availability of targeted drug therapy for specific somatic mutations, the strength of association of selected genes with breast cancer, frequency of these variants, reimbursement, and choice of PCR based genotyping versus next-gen sequencing. The final session focused on the creation of a genomic pathology report for this patient after analyzing the clinical significance of each result from multi-gene mutational analysis using free web-based tools.

This workshop was a great introduction for the genomics neophyte (especially if one’s residency is weak in this subject or doesn’t have a molecular pathology rotation) and even someone with some experience like myself, learned how to use some new tools and applications even though the concepts were not new to me. As I mentioned in previous blogs, I learn more from having to tackle issues hands-on and being able to participate in a bidirectional discussion about a topic versus reading textbooks or attending lectures. The workshop was a good intro albeit too short to learn to apply these skills comfortably and effectively…but it is definitely a step in the right direction and I expect to see more great things coming out of the TRIG Working Group. More info about TRIG is at www.ascp.org/trig.

-Betty Chung

Lab Product Friday

Nanosphere’s motto is “advancing diagnostics through the power of nanotechnology.” While I’ve read enough science fiction to quibble with the “nanotechnology” designation, Nanosphere does seem to have a handle on rapid molecular testing. The Verigene System can analyze samples for respiratory viruses (Influenza A, Influenza B, RSV, and 2009 H1N1, to name a few), C. difficle, and gram-negative or gram-positive organisms in positive blood culture bottles.

While other rapid molecular analyzers exist for C. difficle and respiratory viruses, I’m intrigued by the blood culture analysis. Literature from the company claims that analyzing one sample using one cartridge can give you identification and resistance information for organisms commonly implicated in septicemia. With the rising prevalence of multidrug resistant bacteria such as MRSA, CRE, and Acinetobacter baumanii, getting these results almost two days faster than current methodologies would have a positive impact on patient care.

A recent study suggests that this system does what it claims to do–rapidly identify organisms and resistance patterns in positive blood cultures.

Have any of you tried this system? If so, what are your thoughts?